B16.1 Acute hepatitis B with delta-agent without hepatic coma

Name of the Condition

• Acute hepatitis B with delta-agent without hepatic coma

Summary

Acute hepatitis B with delta-agent without hepatic coma is a viral infection characterized by liver inflammation caused by co-infection with the hepatitis B virus (HBV) and the delta agent (HDV). The delta agent requires HBV for replication, and its presence often leads to more aggressive liver damage compared to HBV infection alone. This condition does not involve hepatic coma, which is severe liver failure resulting in impaired consciousness.

Causes

Acute hepatitis B with delta-agent without hepatic coma is caused by co-infection with the hepatitis B virus (HBV) and the delta agent (HDV). The delta agent is a defective virus that depends on HBV to replicate. Transmission occurs through contact with infectious blood or bodily fluids, including unprotected sexual contact, sharing needles, or perinatal exposure. The combination of HBV and HDV accelerates liver damage, increasing the risk of severe disease.

Risk Factors

• Co-infection with hepatitis B and delta agents
• Intravenous drug use with shared needles
• Unprotected sexual contact with an infected person
• Occupational exposure to blood (e.g., healthcare workers)
• Living in regions with high HBV/HDV prevalence
• Perinatal transmission from an infected mother

Symptoms

• Severe fatigue and malaise
• Jaundice (yellowing of the skin and eyes)
• Nausea, vomiting, or abdominal pain
• Loss of appetite
• Dark urine or clay-colored stools
• Fever and chills

Diagnosis

Diagnosis involves blood tests to detect HBV and HDV antigens and antibodies, as well as liver function tests to assess liver damage. Imaging studies or liver biopsy may be used to evaluate the extent of inflammation or fibrosis. Clinical evaluation includes assessing symptoms and risk factors for co-infection.

Treatment Options

Treatment focuses on supportive care, including rest, proper nutrition, and hydration. Antiviral medications may be used to manage severe cases or prevent progression to chronic infection. Monitoring liver function and viral load is essential to guide management and detect complications early.

Prognosis and Follow-Up

Prognosis depends on the severity of liver damage and the patient’s overall health. Most acute cases resolve within weeks to months, but co-infection with HDV may increase the risk of chronic hepatitis or cirrhosis. Follow-up care includes regular monitoring of liver function and viral markers to assess recovery or progression.

Complications

Potential complications include acute liver failure, chronic hepatitis B or D, cirrhosis, or liver cancer. Severe cases may require hospitalization for supportive care or liver transplantation. Early detection and management can reduce the risk of long-term liver damage.

Lifestyle & Prevention

Preventive measures include vaccination against HBV, avoiding sharing needles or personal items that may contact blood, practicing safe sex, and ensuring proper sterilization of medical equipment. Individuals at high risk should be screened for HBV and HDV to enable early intervention.

When to Seek Professional Help

Seek medical attention if symptoms such as jaundice, severe abdominal pain, or persistent fatigue occur, as these may indicate worsening liver function. Prompt evaluation is critical for severe cases or if risk factors for co-infection are present.

Tips for Medical Coders

Document the presence of the delta agent (HDV) and confirm the absence of hepatic coma to accurately assign this code. Ensure clinical documentation supports co-infection with HBV and HDV and verifies no evidence of hepatic coma. Code B16.1 is specific to acute hepatitis B with delta-agent without hepatic coma; verify no conflicting documentation before assignment.